Compare DRUG & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRUG | BNTC |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.8M | 365.1M |
| IPO Year | N/A | N/A |
| Metric | DRUG | BNTC |
|---|---|---|
| Price | $75.85 | $13.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $83.00 | $26.00 |
| AVG Volume (30 Days) | 193.8K | ★ 276.4K |
| Earning Date | 12-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $9.49 |
| 52 Week High | $81.33 | $17.15 |
| Indicator | DRUG | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 76.86 | 51.20 |
| Support Level | $69.12 | $11.54 |
| Resistance Level | $75.99 | $13.17 |
| Average True Range (ATR) | 4.20 | 0.84 |
| MACD | 1.55 | 0.07 |
| Stochastic Oscillator | 88.57 | 84.44 |
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.